Exhibit 10.1
| EXECUTION COPY |
DISTRIBUTION AGREEMENT
THIS AGREEMENT is entered and executed as of October 9th, 2012 (“Effective Date”), by and between TranS1 Inc., a Delaware corporation with its principal place of business at 301 Government Center Drive, Wilmington, NC 28403 (“TRANS1”) and Jiade Sunshine, a limited liability incorporated in the People’s Republic of China with its principal place of business at Room 315, West 3 Building, No.83 Fuxing Road, Haidian District Beijing China, Post code:100039 (“Distributor”).
WHEREAS,TRANS1 develops, manufactures and markets devices for the treatment of spine disorders;
WHEREAS,Distributor provides sales, marketing and distribution services to third parties; and spine surgeons in the defined territory and or country.
WHEREAS,TRANS1 wishes to appointDistributor as its sole and exclusive distributor for the marketing and promotion of the Products in the Territory in the Field, provided, however, thatTRANS1 reserves the right to sell the Products directly in the Territory outside of the Field.
NOW, THEREFORE, the parties hereto agree as follows:
1. Definitions.
(a) “Contract Year” means the period beginning on the Effective Date and ending October 31, 2013, and each twelve (12) consecutive month period thereafter.
(b) “Field” shall mean medical devices intended to access or treat degenerative disc disease and motion preservation of the lumbar spine as applicable.
(c) “Marketing Plan” shall refer to the marketing plan for the Products developed byDistributor with input fromTRANS1.
(d) “Products” shall mean all ofTRANS1’s current and future AxiaLIF brand products, including all of its delivery devices and related access devices and procedures, procedure-specific and implantable devices in the Field; the current products approved for sale in the Territory are listed onExhibit A, as amended from time to time by the parties.
(e) “Promotional Materials” shall have the meaning set forth in Section 3(e)(iii).
(f) “Services” shall mean the inventory management and administrative services thatDistributor shall provide forTRANS1 under this Agreement.
(g) “Territory” shall mean the geographic area set forth inExhibit B as may be amended from time to time by mutual agreement of the parties.
| 1 |
| EXECUTION COPY |
2. Appointment and Quarterly Reviews.
(a) General. Subject to this Agreement,TRANS1 hereby appointsDistributor, andDistributor hereby accepts its appointment as TRANS1’s sole and exclusive (subject to Section 4(a)) distributor to promote, market and sell the Products in the Territory in the Field, provided, however, thatTRANS1 reserves the right to sell the Products directly in the Territory outside of the Field.
(b) Quarterly Review. On a quarterly basis, senior level sales or marketing representatives fromTRANS1 andDistributorwill meet to review sales progress,Distributor performance, ASP (average selling price) versus target prices, product performance issues, quality issues and to resolve in good faith outstanding strategy and tactical issues that arise during the Term, and to review all aspects of marketing the Products. This will typically occur as part ofDistributor’s quarterly reviews.
3. Distributor’s Obligations.
(a) General.Distributor will use commercial best efforts to (i) promote, market and sell the Products within the Territory; (ii) manage distribution of the Products within the Territory and (iii) perform the Services in a good and workmanlike manner. Upon receipt of prior written consent fromTRANS1,Distributor may subcontract the performance of any of its obligations under this Agreement to any third party distributor.
(b) Orders.
(i) Initial Order. Within thirty (30) days of the Effective Date,Distributor shall submit an initial purchase order for [***] Products and [***] Products (the “Initial Order”).TRANS1 shall deliver the quantity of Product set forth inExhibit G against the Initial Order in accordance with Section 4(b) on or before December 31st, 2012. The balance of the quantity of Product in the Initial Order shall be delivered pursuant to the Quarterly Forecasts submitted byDistributor pursuant to Section 3(e)(iv). TRANS1 may terminate this Agreement upon written notice and with immediate effect (withoutDistributor having the opportunity to cure) in the eventDistributor fails to submit the Initial Order in accordance with this Section 3(b)(i).
(ii) Annual Orders. On or before each October 31 of each Contract Year,Distributor shall submit a purchase order for the quantity of Product it wishes to purchase in the following Contract Year (each, an “Annual Order”); provided, however, that in no event shall an Annual Order be for less than the following:
(A) Distributor shall order on or before October 31, 2013 no less than [***] Products, and on or before each October 31 during the remainder of the term of this Agreement,Distributor shall order no less than [***]Products.
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 2 |
| EXECUTION COPY |
(B) Distributor shall order on or before each of October 31, 2012 and 2013 no less than [***] Products, and on or before each of October 31during the remainder of the term of this Agreement,Distributor shall order no less than [***] Products.
(C) Each Annual Order shall provide for delivery of at least [***]% of the [***] Products and at least [***]% of the [***] Products on or before December 31 of that Contract Year.
(iii) TRANS1 shall deliver an initial quantity of Product designated in the applicable Annual Order in accordance with Section 4(b), and shall deliver the balance of the quantity of Product in the Annual Order shall be delivered pursuant to the Quarterly Forecasts submitted byDistributor pursuant to Section 3(e)(iv).TRANS1 may terminate this Agreement upon written notice and with immediate effect (withoutDistributor having the opportunity to cure) in the eventDistributor fails to submit an Annual Order in accordance with this Section 3(b)(ii).
(iv) Additional Orders.Distributor may submit additional orders for Products during a Contract Year (each, an “Additional Order”).TRANS1 shall deliver Product ordered pursuant to an Additional Order in accordance with Section 4(b). For the avoidance of doubt,TRANS1 shall not be obligated to delivery of Product ordered pursuant to an Additional Order, however, if TRANSI decides not to deliver the Additional Orders, it shall timely notify Distributor pursuant to Section5a(ii).
(v) Shortfall in Orders. If Distributor does not request delivery of all units of Product in the Initial Order or in any Annual Order by the end of the applicable Contract Year (e.g., by October 31, 2013 in the case of the first Contract Year), then so long as Distributor has timely paid for the order in accordance with Section 6, Distributor may request that such pre-paid units be delivered on any date during the immediately following Contract Year and TranS1 shall ship such units in accordance with Section 4(b). Such units shall not be credited towards or otherwise affect Distributor’s obligation to purchase [***] Products for the Contract Year in which they are delivered. If Distributor does not make a timely request for delivery of such units by the end of the Contract Year immediately following the Contract Year for which they were originally ordered, TranS1 shall have no further obligation to ship such units and shall be entitled to retain the full amount invoiced for such units.
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 3 |
| EXECUTION COPY |
(c) Facilities and Staff.Distributor will acquire and maintain the facilities and staff that it in its sole discretion deems appropriate to effectively market and sell the Products throughout the Territory.
(d) Training.Distributorwill provide, with the participation ofTRANS1, eachDistributor employee with the training necessary, on two agreed-upon occasions within the ninety (90) day period from the Effective Date, forDistributor to market the Products within the Territory. In addition,Distributor shall provide surgeon training as required byTRANS1 in the Territory and in the Field.Distributor will be responsible for all costs of the surgeon training, product and lab expenses, less theTRANS1 employee support and or approved US surgeon proctor that is agreed upon in writing prior to the scheduled event. Further,TRANS1 will provide access to specific soft tissue training models at a predetermined transfer price of manufacturing with quantity and forecasts to be provided byDistributor.TRANS1 shall not promote, market and/sellProducts directly or indirectly to the surgeons trained byDistributor or to any hospitals or institutes with which such surgeons work or are associated.
(i) SURGEON TRAININGDistributor agrees that each customer (surgeon) will be trained and certifiedas trained by TRANS1 prior to any surgical procedure using Product. Failure to do so will result in immediate termination of this contract.
(e) Inventory Management and Lot Traceability.Distributor agrees to maintain records that provide for lot and serial number traceability of Products to the end user.Distributor is required to complete a Case Inventory Form (CIF), as provided in in Exhibit F, for EVERY case completed in Territory. Failure to do so will result in immediate termination of this contract.
(i) Marketing and Promotional Activities.Distributor will market the Products within the Territory according to the then current Marketing Plan. A marketing plan template is provided inExhibit E.Distributor will provideTRANS1 with an annually completed Marketing Plan by January 31st of each year.Distributor will provideTRANS1 with notice of upcoming trade shows and similar events within the Territory on a quarterly basis.
(ii) Marketing Support. Marketing of the Products shall be the responsibility ofDistributor.Distributor shall provide marketing support to help effectively market the Products within the Territory, including without limitation, marketing studies, marketing communications and attendance at trade shows.Distributor shall provide a Product Manager, who is dedicated toTRANS1 Products and commercialization activities in the Territory.
(iii) Promotional Materials.Distributor will use the brochures and other sales and promotional literature describing the Products thatTRANS1 periodically approves via theTRANS1 quality systems or provides toDistributor (the “Promotional Materials”).Distributor will translate or adapt the Promotional Materials for use within the Territory.Distributor will provideTranS1 with copy of translated Promotion Material for review prior to distribution in Territory. Distributor hereby assigns toTRANS1 the copyrights thatDistributor may acquire or possess in translations and adaptations of the Promotional Materials.
| 4 |
| EXECUTION COPY |
(iv) Forecasts.Distributorwill provide quarterly total demand forecasts for the Territory toTRANS1 for demand planning, on a rolling twelve-month basis, and no later than the beginning of each calendar quarter a rolling four (4) calendar quarter total demand forecast for the Territory toTRANS1 (each, a “Quarterly Forecast”). The quarterly forecast shall be binding onDistributor.Distributor will also provide quarterly toTRANS1 a twelve month rolling revenue forecast for the Territory. These forecasts do not alter the agreed upon minimum sales requirements.
(v) Prices.Distributor will quote to customers the prices and terms for the Products based upon the pricing levels and discount levels established byDistributor in its sole discretion, provided, however, thatDistributor shall not quote or sell at any price below the price floor established byTRANS1 withoutTRANS1’s prior written consent.
(vi) Records and Reports.Distributor will keep accurate records of its activities under this Agreement, including a record of (i) each sale and the price of such sale; and (ii) each invoice issued to and payment received from a customer. Within 15 days of the end of each one-month period of this Agreement,Distributor will provideTRANS1 with a report showing the sales made of the Products and the actual sales price for such Products.
(vii) Product Complaints.Distributorwill promptly provide notice toTRANS1 of the occurrence of any of the following within the Territory: (a) receipt of any Product quality claims or complaints or other written legal claims or complaints, (b) receipt of any medical claims, complaints or problems, or (c) receipt of any written communication from any applicable regulatory agency pertaining to the Products. FAILURE TO MEET THIS OBLIGATION AND COMPLY WITH ANY REGULATORY AUTHORITIES AND IN COUNTRY REPORTING REQUIREMENTS CAN RESULT IN IMMEDIATE TERMINATION FOR CAUSE AND NO CURE PERIOD WILL BE ALLOWED.
| 5 |
| EXECUTION COPY |
4. TRANS1’s Obligations.
(a) Distribution Management Phase-In.TRANS1 has disclosed toDistributor all distribution agreements betweenTRANS1 and distributors within the Territory as of the date hereof. The parties agree to cooperate in good faith to arrange to have an identified third party with limited distribution rights to Products in southern China become a sub-distributor (i.e., such third party would purchase Products from Distributor for resale in a portion of the Territory as agreed between Distributor and such third party). Promptly following joint written notice from Distributor and the third party that they have reached agreement regarding the sub-distribution arrangement, TRANS1 shall cease shipments of Products for use in the Field in the Territory to the third party. The third party may continue to sell Products purchased or ordered prior to the delivery of such joint notice to TRANS1. Subject to the foregoing, TRANS1 confirms thatDistributor is the sole distributor in the Territory.
(b) Orders.TRANS1will use its commercially reasonable efforts to promptly fill all orders received fromDistributor and accepted byTRANS1 in accordance with Section 5.
(c) Provision of Sample Units. If requested byDistributor and approved in advance byTRANS1 (such approval not to be unreasonably withheld),TRANS1 shall supplyDistributor with a reasonable number of sample Products annually atTRANS1’s predetermined transfer price of such non-sterile Products for demonstration and marketing purposes.
(d) Promotional Materials.TRANS1will provide toDistributor out of its existing stock the quantity and quality of Promotional Materials in English as the parties deem reasonably sufficient forDistributor and its distributors to promote, solicit and obtain orders for the Products within the Territory in accordance with the Marketing Plan.
(e) Training.TRANS1 will provide, with the participation ofDistributor, eachDistributor employee with the training necessary, [***] within the ninety (90) day period from the Effective Date, forDistributor to market the Products within the Territory. In additionTRANS1 shall provide additional training as requested byDistributor for any future Product introductions and/or modifications in the Territory in the Field.TRANS1 will provide access to specific soft tissue training models at a predetermined transfer price with forecasts to be provided byDistributor. FAILURE TO TRAIN DISTRIBUTOR EMPLOYEES WITHIN THE 90 DAY PERIOD WILL RESULT IN TERMINATION FOR CAUSE AND NO CURE PERIOD WILL BE ALLOWED.
(f) Product Changes. Except in the case of a Product recall or other emergency,TRANS1 will provideDistributor a minimum of 30 day notice of changes contemplated in Products or packaging, or advertising, sales or Promotional Materials relating to the Products or any significant development planned and improvements that may affect the marketing of the Products.
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 6 |
| EXECUTION COPY |
(g) Support.TRANS1 will provideDistributor, in the form and when reasonably required byDistributor, access toTRANS1’s technical and marketing and sales personnel for advice, consultation and assistance in marketing, negotiation of sales of, and providing support for the Products within the Territory.TRANS1 may provide such support by telephone or other forms of communication or by on-site visits, as the parties deem appropriate.TRANS1 will provide executive sales support as deemed necessary byTRANS1.
(h) Leads.TRANS1may generate and will refer toDistributor all leads for potential customers of the Products within the Territory in the Field. To refer a lead,TRANS1 will complete a Lead Referral form and remit it toDistributor.Distributor will follow-up on such leads according to the Marketing Plan.
(i) Sales Strategy. When and if requested byDistributor,TRANS1 will participate in quarterly sales strategy sessions withDistributor management.
(j) Regulatory Approvals, Compliance with Laws.TRANS1 shall be solely responsible to obtain the registrations, approvals or licenses that may be required to sell in the Territory.TRANS1 will be solely responsible for all regulatory matters (other than those required to import and sell the Products within the Territory) including, securing any and all regulatory approvals, performing all clinical trials, and applying to register theTRANS1 trademarks, patents or other intellectual property within the Territory.Distributor will cooperate withTRANS1 to obtain necessary regulatory approval and comply with all applicable local laws and regulations. TRANS1 shall use commercially reasonable efforts to complete the registrations of the Products in the Territory as soon as possible in order to assure thatDistributor will be able to commercialize the Products as expected.
(k) Product Recalls. In the event of a recall ordered or requested by any government agency, a court or by either party of any Product within the Territory,Distributor andTRANS1 will discuss actions that will be taken with respect to customers and government authorities in implementing such recall, including in locating and retrieving recalled Products from customers. The parties will agree on such actions prior to implementation of any Product recall. In the event the parties cannot agree on such actions,TRANS1 will be solely responsible for the implementation of such Product recall. Any such recall of Products within the Territory, whether required or voluntary, will be atTRANS1’s cost and expense, except to the extent the recall was caused by a breach of this Agreement byDistributor or the negligence or willful misconduct ofDistributor, its employees, agents or contractors. In the event of a Product Recall, the parties to this Agreement agree to a proportionate reduction in the Annual Order for the applicable period.
(l) Product Complaints. Each party shall, within five (5) business days of occurrence, provide notice to the other party of the occurrence of any of the following: (a) receipt of any Product quality claims or complaints or other written legal claims or complaints, (b) receipt of any medical claims, complaints or problems, or (c) receipt of any written communication from any applicable regulatory agency pertaining to the Products. TRANS1 shall be responsible for handling of the complaint.
| 7 |
| EXECUTION COPY |
(m) Consulting Agreements.TRANS1 shall be solely responsible for any consulting agreements it has in place, and payments under those agreements, and the termination of any agreements that conflict with the rights and responsibilities being granted toDistributor in this Agreement.
5. Orders, Shipment and Acceptance.
(a) Standard Purchase Orders.
(i) All orders of Products shall be onDistributor’s then current standard purchase order. The provisions of this Agreement shall prevail over any inconsistent statements or additional statements or provisions, rights and obligations contained in any document related to this Agreement passing between the parties hereto including, but not limited to, any purchase order, acknowledgement, confirmation or notice.
(ii) Orders shall be submitted by mail, email or facsimile, or by other means agreed upon by the parties. All orders and modifications to orders are subject to acceptance byTRANS1; provided, however, thatTRANS1 shall accept all purchase orders byDistributor for the Products so long as such orders are in accordance with the most recent rolling forecast in effect that have been accepted byTRANS1.TRANS1 shall use commercially reasonable efforts to fill all orders byDistributor for the Products hereunder. IfTRANS1 believes that it will not be able to satisfyDistributor’s order for the Products,TRANS1 shall promptly, and in no event later than five (5) business days after receipt thereof, notifyDistributor, specifying the reasons for the delay and the expected duration.TRANS1 shall use its commercially reasonable efforts to deliver all orders that are accepted in accordance with the delivery date set forth in the applicable purchase order so long as such delivery date is in accordance with the most recent rolling forecast in effect.
(b) Terms of Shipment, Taxes and Duties.TRANS1 shall arrange for shipment and invoicing toDistributor of the Products ordered byDistributor, via common carrier selected byDistributor, EXW (Incoterms 2010)TRANS1’s manufacturing facility and shipped toDistributor’s facility for all deliveries.TRANS1’s title and risk of loss to the Products shall pass toDistributor upon delivery of the Products to the carrier.Distributor shall pay all freight, insurance, duties and other shipping expenses.
(c) Product Specifications. All Products shall conform, in all material respects, to the written specifications for the Product in effect as of the date of delivery (“Product Specifications”) and be ready for end-user sale, including all packaging, labeling, instructions-for-use and sterilization.
(d) Return of Product. Within five (5) days of receiving the Products,Distributor may reject any of such Products which in its good faith determination fail to meet the applicable Product Specifications in all material respects or which do not meet the product warranties contained herein by sendingTRANS1 notice of the lot numbers of rejected Products, together with a description of the specific reason for rejection.Distributor shall, within ten (10) days of notice, return toTRANS1, atTRANS1’s expense, any such rejected Products, which may be replaced byTRANS1 within thirty (30) days of receipt.Distributor shall not be required to payTRANS1 for any Products which have been properly rejected in accordance with this Section 5.1(d), and which have not been replaced byTRANS1. Any Product not rejected byDistributor within the thirty (30) day period shall be deemed to have been accepted, provided that the warranties provided in Section 9 shall survive the acceptance of the Product byDistributor for a period of [***] from delivery toDistributor; provided, however, thatDistributor’s sole remedy, andTRANS1’s sole obligation with respect to a breach of such warranty shall be to repair or replace such Product.TRANS1shall perform a review of the Product returned byDistributorand shall use commercially reasonably efforts to implement necessary adjustments to the Product, if any are required, at the end of the next quarter. IfTRANS1 determines the Product is within specifications and not defective, theDistributor will be responsible for the costs of the return and reshipment of said Product.
| 8 |
| EXECUTION COPY |
6. Price and Payment Terms.
(a) Transfer Price.
(i) Distributor shall payTRANS1 the Transfer Price for the Products delivered to and not rejected byDistributor in accordance with the terms of this Agreement. The Transfer Price for each applicable Product shall be the prices set forth opposite each product listed onExhibit C hereto; andprovided thatTRANS1 shall reserve the right to adjust the Transfer Price for the Products at the discretion of theTRANS1management team and or Board of Directors by delivery toDistributor a revisedExhibit C with 90 days notice to theDistributor prior to such revised prices taking effect. All prices quoted inExhibit C are EXWTRANS1’s manufacturing facility. Possession transfers toDistributor once Product leaves TranS1 location.
(ii) The Transfer Price shall remain unchanged in the first [***] (i.e., for the Initial Order and for any other Products ordered for delivery on or before [***]) and may be evaluated and adjusted thereafter at a minimum once per year and will be based on estimated market prices, competition and profit objectives of all parties then reconciled prior to the conclusion of each calendar year within the term of the Agreement.
(iii) All purchases of the Product hereunder shall be paid byDistributor toTRANS1based in US Dollars.Distributor shall pay for Product purchased pursuant to the Initial Order and any Annual Order as follows: [***]. By way of example, the Initial Order shall be for no less than $1,360,000 ([***] Products @ $[***] per Product plus [***] Products @ $[***] per Product), [***].Distributor shall pay for Product purchased pursuant to an Additional Order within [***] ([***]) days of the date of invoice. Payment byDistributor under this Agreement shall be made by wire transfer or other instrument approved byTRANS1. IfDistributor is delinquent in remitting payments toTRANS1 under the terms specified hereinTRANS1 may, at its option, (a) chargeDistributor interest on past due amounts at a rate of [***] percent ([***]%) per calendar month, provided such interest does not exceed the maximum rate allowed by law; (b) terminate and or modify the exclusivity of this Agreement; (c) in the case of repeated and material delinquencies, require advance payment, payment on delivery, bank letter-of-credit or bank-guaranteed payments for future shipments; and/or (d) with respect to Additional Orders, change the payment term for future invoices from [***] ([***]) days to [***] ([***]) days. Distributor shall comply with such modified payment terms designated byTRANS1. The foregoing remedies ofTRANS1 are not exclusive, but are in addition to any and all remedies available toTRANS1 under this Agreement and applicable law.
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 9 |
| EXECUTION COPY |
(b) Prices. Nothing contained herein, however, shall be deemed to limit in any way the right ofDistributor to determine the prices at which the Products purchased byDistributor may be sold byDistributor to any other distributor or any other customer. The distributor agrees not to sell products in any jurisdiction other than the Territory or knowingly sub-distribute products to others for distribution outside the Territory.
7. Confidentiality;No Competition
(a) During the term of this Agreement, neitherDistributor nor any of its employees, agents or representatives shall:
(i) Manufacture, sell, market or deliver any product, or participate in any manner in such activities, if such product is in competition with any product manufactured, sold, marketed or distributed for sale byTRANS1; provided that ifTRANS1 develops a new product which is competitive with any product then being sold or marketed byDistributorfor another person or entity,Distributor shall have ninety days following notice fromTRANS1 to cease marketing and selling the competing product;
(b) Information. Each party acknowledges that it may disclose certain confidential information (the “Information”) to the other party. If either party discloses such Information to the other, the receiving party will (i) use at least the same degree of care to maintain the secrecy of such Information as the receiving party uses to maintain the secrecy of its own confidential information and (ii) use the Information only to accomplish the purposes of this Agreement. The disclosing party will mark as “confidential” all tangible items supplied to the receiving party that contain Information of the disclosing party. Within 20 days of any oral disclosures of Information, the disclosing party will provide the receiving party with a writing memorializing the Information disclosed and the date of disclosure. The placement of copyright notices on such items will not constitute publication or otherwise impair their confidential nature.
(c) Disclosure. Neither party will disclose the Information of the disclosing party to any person except those of the receiving party’s employees or agents that require access to accomplish the purposes of this Agreement and have been made aware of the confidentiality obligations herein. If the receiving party learns of an actual or potential unauthorized use or disclosure of the disclosing party’s Information, the receiving party will promptly notify the disclosing party and, at the disclosing party’s request, provide the disclosing party with reasonable assistance to recover its Information and to prevent subsequent unauthorized uses or disclosures of such Information. Each party acknowledges that (i) the unauthorized use or disclosure of any Information of the disclosing party will cause irreparable damage for which it will not have an adequate remedy at law and (ii) the disclosing party will be entitled to injunctive and other equitable relief in such cases.
(d) Limitations. Neither party will have any confidentiality obligation with respect to the confidential information of the disclosing party that (i) the receiving party independently knew or develops without using the Information of the disclosing party, (ii) the receiving party lawfully obtains from another person under no obligation of confidentiality or (iii) is or becomes publicly available other than as a result of an act or omission of the receiving party or any of its employees or agents.
| 10 |
| EXECUTION COPY |
8. Ownership.
All patents, copyrights, trademarks, trade secrets, regulatory approvals and other proprietary rights in or related to the Products are and will remain the exclusive property ofTRANS1 or its licensors, whether or not specifically recognized or perfected under applicable law. During the term of this Agreement,Distributor may useTRANS1’s trademarks to promote the Products, provided that prior to publishing or disseminating any advertising or promotional material bearingTRANS1’s trademarks,Distributor will deliver a sample of such materials to TRANS1 for prior approval. Nevertheless, TRANS1 shall use commercially reasonable efforts to promptly register its trademarks with the authorities in the Territory.
9. Representations and Warranties.
(a) Existence and Authority. Each party represents and warrants that it is a corporation duly organized, validly existing and in good standing under the laws of its jurisdiction of incorporation and has the corporate power and authority to execute, deliver and perform this Agreement. The execution of this Agreement and the performance thereof have been duly authorized by all necessary corporate action on its part and do not conflict with the terms or conditions of any agreement to which such party is subject.
(b) Products.TRANS1 represents and warrants that the Products will (i) conform to the Product Specifications and (ii) comply with the requirements of any applicable law or regulation.
(c) Intellectual Property.TRANS1 represents and warrants that it has all necessary ownership rights to market, sell and distribute the Products in the Territory, and that the manufacture, sale and use of the Products and any distribution of the Promotional Materials will not infringe any patents, copyrights, trademarks or other intellectual or proprietary rights of any third parties.
(d) Disclaimer. EXCEPT AS OTHERWISE PROVIDED IN THIS AGREEMENT, ALL WARRANTIES, CONDITIONS AND REPRESENTATIONS WITH RESPECT TO THE PRODUCTS OR THE PROMOTIONAL MATERIALS, WHETHER EXPRESS OR IMPLIED, ARISING BY LAW, CUSTOM, PRIOR ORAL OR WRITTEN STATEMENT BY THE PARTIES OR OTHERWISE (INCLUDING, BUT NOT LIMITED TO ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, TITLE AND NON-INFRINGEMENT) ARE HEREBY OVERRIDDEN, EXCLUDED AND DISCLAIMED.
| 11 |
| EXECUTION COPY |
10. Limitation of Liability.
UNDER NO CIRCUMSTANCES WILL EITHER PARTY BE LIABLE FOR ANY CONSEQUENTIAL, INDIRECT, SPECIAL, PUNITIVE OR INCIDENTAL DAMAGES OR DIRECT OR INDIRECT LOST PROFITS, WHETHER FORESEEABLE OR UNFORESEEABLE, BASED ON CLAIMS OF THE OTHER PARTY OR ITS CUSTOMERS (INCLUDING, BUT NOT LIMITED TO, CLAIMS FOR LOSS OF GOODWILL, USE OF MONEY OR USE OF THE PRODUCTS, INTERRUPTION OF STOPPAGE OF WORK OR IMPAIRMENT OF OTHER ASSETS), ARISING OUT OF BREACH OR FAILURE OF EXPRESS OR IMPLIED WARRANTY, BREACH OF CONTRACT, MISREPRESENTATION, NEGLIGENCE, STRICT LIABILITY IN TORT OR OTHERWISE.
11. NO DAMAGES.
TRANS1 SHALL NOT BE LIABLE FOR ANY DAMAGES, WHETHER INCIDENTAL, CONSEQUENTIAL OR OTHERWISE, FOR A FAILURE TO FILL ORDERS, DELAYS IN SHIPMENT OR DELIVERY, OR ANY ERROR IN FILLING AN ORDER.
12. Audit.
During the term of this Agreement and for one year after its expiration or termination,TRANS1 or its accountants may, upon 30 days’ prior notice toDistributor, audit the accounting records ofDistributor during the normal working hours to verifyDistributor’s compliance with the obligations under this Agreement; provided, however, thatTRANS1 will not be entitled to conduct such audit more than once per year.
13. Indemnity.
Except for liabilities to the extent caused by acts ofDistributor which are outside the scope of its authority under this Agreement, a breach of this Agreement byDistributor,Distributor’s failure to comply with applicable laws, or the negligence or willful misconduct ofDistributor, its employees, agents or contractors,TRANS1 will indemnify, defend and hold harmlessDistributorfrom and against any and all liabilities, losses, suits, claims, damages and expenses (including attorneys’ fees and costs) to the extent based on claims arising out of or relating to (i) the manufacture, use, distribution, promotion or sale of the Products, or (ii) the infringement of any patent, copyright, trademark or other intellectual property rights of any third parties with respect to the Products or Promotional Materials (except to the extent caused by contributions made to the Promotional Materials byDistributor).Distributorwill (i) notifyTRANS1 promptly of any such actual or potential claim; (ii) allowTRANS1 to control the defense of the claim; (iii) cooperate in the defense of such claim and (iv) not settle such claim withoutTRANS1’s consent.
Distributorwill indemnify, defend and hold harmlessTRANS1 from and against any and all liabilities, losses, suits, claims, damages and expenses (including attorneys’ fees and costs) to the extent based on claims arising out of or relating to (i) acts ofDistributor which are outside the scope of its authority under this Agreement, (ii) a breach of this Agreement byDistributor, (iii)Distributor’s failure to comply with applicable laws, (iv) the negligence or willful misconduct ofDistributor, its employees, agents or contractors, and (v) the infringement byTRANS1 of any patent, copyright, trademark or other intellectual property rights of any third parties with respect to any portion of the Promotional Materials created byDistributor.TRANS1 will (i) notifyDistributorpromptly of any such actual or potential claim; (ii) allowDistributorto control the defense of the claim; (iii) cooperate in the defense of such claim and (iv) not settle such claim withoutDistributor’s consent.
| 12 |
| EXECUTION COPY |
14. Term and Termination.
(a) Term. This Agreement will become effective on the Effective Date and continue in effect for four (4) years thereafter, unless earlier terminated pursuant to paragraph 14(b). This Agreement is renewable for up to four (4) subsequent one (1) year renewal periods if both parties agree in writing at least 90 days prior to the expiration of the initial term or any renewal term of its intention not to renew.
(b) Termination for Cause. Either party may terminate this Agreement, without judicial or administrative notice or resolution, immediately upon notice to the other party if:
(i) the other party or any of its employees breaches any material obligation under this Agreement and such party fails to cure the breach within thirty days, unless the clause breached expressly excludes a cure period, after receipt of written notice thereof. Failure byTRANS1 to deliver Products in accordance with the schedule set forth in the forecast for more than three months during any one year period will be considered breach of a material obligation;
(ii) the other party or any of its employees breaches any material obligation under this Agreement that expressly excludes a cure period.
(iii) either party ceases to conduct business in the normal course, is declared insolvent, undergoes any procedure for the suspension of payment, makes a general assignment for the benefit of creditors or a petition for bankruptcy, reorganization, dissolution or liquidation is filed by or against it; or
(iv) the direct or indirect ownership or control of the other party changes as follows:TRANS1 may only exercise its right of termination under this Section in the event that the ownership ofDistributor changes by more than 50%.Distributor may only exercise its right of termination under this Section if a third party gains control ofTRANS1 from, or subsequent to, the date hereof. Control ofTRANS1 will be deemed to have changed to a third party if that party acquires control over 50% or more of the voting shares ofTRANS1. If one party chooses not to terminate this Agreement upon the occurrence of the said event of the other party with the other party’s notice, this Agreement shall be continuously binding upon both parties, and both parties shall assure that it will continuously perform their obligations thereunder.For purposes of this Section, an initial public offering of a party will not be considered to create a right of termination under this Agreement.
(c) Termination for Failure to Purchase Minimum Requirements.TRANS1 may terminate this Agreement, as provided for in Section 3(b) if Distributor fails to submit the Initial Order or any Annual Order.
(d) Termination for Change of Control. In addition to the rights in 14(b)(iv), in the event of a change of control of either party, the party undergoing the change of control may terminate this Agreement by providing written notice to the other within 30 days of such change of control. [***].
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 13 |
| EXECUTION COPY |
(e) Consequences of Termination. Upon expiration or termination of this Agreement for any reason the parties will comply with the following termination obligations:
(i) Distributor will pay all due and outstanding amounts.
(ii) Distributorwill, atTRANS1’s option, destroy or deliver toTRANS1 or its designees all Promotional Materials withinDistributor’s possession or control, provided, ifTRANS1 is the party terminating,TRANS1shall reimburseDistributor for all direct and indirect costs associated with producing such materials.
(iii) Distributor is required to return all Products, atTRANS1’s expense, within 30 days of termination. There will be no refund issued for any returned Product.
(f) Survival. The provisions of Sections 3.e.(vii), 4(k) and (l), 5(d), 7, 8, 10, 11, 12, 13, 14, 15, 18 and 23 will survive the expiration or termination of this Agreement.
15. Insurance.
TRANS1 will maintain product liability insurance in an amount sufficient to cover complete cost of product liability, regulatory and intellectual property liability with an insurance company rated at least A+3 by Best’s rating guide.Distributor will maintain insurance in an amount sufficient to cover anyDistributor warehousing facilities and to cover wrongful acts byDistributor in the distribution, sale and promotion of the Products.
16. U.S. Export Restrictions.
Distributor acknowledges that the Products and related information, documents and materials may be subject to export controls under U.S. Export Administration Regulations.Distributor will (i) comply with all legal requirements established under these controls, (ii) cooperate withTRANS1 in any official or unofficial audit or inspection that relates to these controls and (iii) not export, re-export, divert or transfer any such item or direct products thereof to any country to which such transfer is prohibited by such export controls, unlessDistributor has obtained the prior written authorization ofTRANS1 and the U.S. Department of Commerce.
| 14 |
| EXECUTION COPY |
17. Force Majeure.
Neither party will be liable for any failure or delay in performing an obligation under this Agreement that is due to causes beyond its reasonable control, such as natural catastrophes, governmental acts or omissions, laws or regulations, labor strikes or difficulties, chaos, terrorist activities, war or transportation stoppages. These causes will not excuse either party from paying amounts due to the other through any available lawful means acceptable to the other party.
18. Notices.
Any notice required or permitted under this Agreement shall be in writing and either mailed by nationally recognized overnight courier, registered or certified mail, return receipt requested, or by express delivery service to the other party. All notices shall be sent to the attention of the Chief Executive Officer of such other party at the address set forth in the first paragraph of this Agreement or at such other addresses or to such other persons as such party may previously have designated by written notice. Notice will be deemed to have been given upon receipt.
19. Foreign Corrupt Practices Act (FCPA)Distributor is required to abide with all requirements of United States FCPA. FCPA guidelines are available on-line athttp://www.fcpa.us
20. Assignment.
Except as otherwise provided, neither party may assign, delegate, subcontract or otherwise transfer this Agreement or any of its rights or obligations without the other party’s prior approval, which approval will not be unreasonably withheld.
21. Waiver, Amendment, Modification.
Except as otherwise provided, any waiver, amendment or other modification of this Agreement will not be effective unless in writing and signed by the party against whom enforcement is sought.
22. Severability.
If any provision of this Agreement is held to be unenforceable, in whole or in part, such holding will not affect the validity of the other provisions.
23. Governing Law and Dispute Resolution.
This Agreement will be governed by and interpreted in accordance with the laws of the State of North Carolina, excluding its conflict of laws principles. Any claim arising out of or relating to this Agreement or the existence, validity, breach or termination thereof, whether during or after its term, will be brought in, and the parties hereby consent to the jurisdiction of, the federal courts sitting in Wilmington or Raleigh, North Carolina.
| 15 |
| EXECUTION COPY |
24. Entire Agreement.
This Agreement and its Exhibits constitute the complete and entire statement of all terms, conditions and representations of the agreement betweenTRANS1 andDistributor with respect to its subject matter and supersedes all prior writings or understandings.
25. Copy and Language
This Agreement shall be executed in multiple copies, each of which is original and with identical legal effect. This Agreement shall be made in both English and Chinese. In case there is any difference or conflict between the two versions, the English version shall prevail.
[No Text Below]
| 16 |
| EXECUTION COPY |
[Signature Page of DISTRIBUTION AGREEMENT]
IN WITNESS WHEREOF,TRANS1 andDistributor cause this Agreement to be executed by their duly authorized representatives identified below.
| TranS1 | Jiade Sunshine | ||||
| : | /s/ Ken Reali | : | /s/ Ming Ming Tian | ||
| : | Ken Reali | : | Ming Ming Tian | ||
| : | President and Chief Executive Officer | : | President | ||
| 17 |
| EXECUTION COPY |
EXHIBIT A
PRODUCT LIST AND CURRENT PRICE LISTS
Prices and product list is as of current International Price List
| · | AxiaLIF Brand Products |
EXHIBIT B
Exclusive in China
For the purpose of this Agreement, China or People’s Republic of China shall not include Hong Kong Special Administrative Region, Macao Special Administrative Region and Taiwan.
| 18 |
| EXECUTION COPY |
EXHIBIT C
2012 PRICE LIST
| AxiaLIF 2L | ||||||||
| Tier | Units | AxiaLIF 1L | S1 Implant | L4-L5 | ||||
| Tier 1 | [***] | [***] | [***] | [***] | ||||
| Tier 2 | [***] | [***] | [***] | [***] | ||||
| Tier 3 | [***] | [***] | [***] | [***] | ||||
| Tier 4 | [***] | [***] | [***] | [***] | ||||
| Tier 5 | [***] | [***] | [***] | [***] | ||||
AXIALIF 1L
| Product | Code | Price | ||
| Axialif 1L Implants | Refer to worksheet | [***] | ||
| 1L Universal Plug (per plug) | TR1-2346 | [***] | ||
| 1L Single Use Instruments | TR1-2200 | [***] | ||
| 1L Reusable Instruments | TR1-1102 | [***] |
AXIALIF 2L
| Product | Code | |||
| Axialif 2L S1 | Refer to worksheet | [***] | ||
| Axialif 2L+ L4/L5 Anchor | Refer to worksheet | [***] | ||
| 1L Single Use Instruments | TR1-2200 | [***] | ||
| 2L Reusable Instruments | [***] | |||
| 2L Single use Instruments | TR1-2207 | [***] | ||
| Facet Screws | Code | |||
| Facet screws (2 per pack) | Refer to worksheet | [***] | ||
| Axialif 360 Disposable Facet Instruments | TR1-2700 | [***] | ||
| Facet Key Wire | TR1-2701 | [***] | ||
| OTHERS | ||||
| Timmy training model (torso reusable Model) | [***] | |||
| Inserts for reusable training model | [***] | |||
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 19 |
| EXECUTION COPY |
EXHIBIT E
Marketing Plan
Major International Congresses attended with surgeons
Annual National Congresses
| Qty. | CATALOG # | DESCRIPTION | |||
| TR1-2905 | AxiaLIF® 1L Stabilization System | Regional Congresses | |||
| TR1-2906 | TranS1® Facet Screw System | ||||
| TR1-2902 | AxiaLIF® 2L Stabilization System |
Direct Marketing
Surgeon Training per month
Sales Rep Training Schedule – first training
Ongoing training-
In country workshops planned
Visiting surgeon travel –
Other Marketing activities
| TR1-2907 | AxiaLIF® 2L™ PLUS Stabilization System | ||||
| TR1-2926 | AxiaLIF® 1L™ PLUS Stabilization System | ||||
| TR1-2910 | TranS1® Vectre™ Facet Fusion System |
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 20 |
| EXECUTION COPY |
EXHIBIT F
| TR1-2201 | AxiaLIF® Tissue Extractor – 4 Pack | ||||
| TR1-2202 | AxiaLIF® Tissue Extractors – 2 Pack | ||||
| TR1-2208 | AxiaLIF ®Tight Disc Cutters – 4 Pack | ||||
| TR1-2217 | AxiaLIF® Endplate Rasps – 2 Pack | ||||
| TR1-2218 | Bowel Retractor | ||||
| TR1-2219 | Conformable Tip Tubular Retractor |
| TranS1® Product Stickers & Lot Numbers | |||
| |||
| |||
| |||
| |||
| |||
| |||
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 21 |
| EXECUTION COPY |
EXHIBIT G
| Surgery Information | ||
| Date of Surgery: | ||
| Surgeon/Location: | ||
| Indication | ||
| Distributor | ||
| Posterior System Use | ||
| List all biologics/ synthetic/ autograft/ allografts used | ||
| 1L Implants | ||||||||
| Catalog # | Description | Units | Each | Total | ||||
| TR1-2300 | TR1-2300: AXIALIF 40MM 10 X 11 | [***] | [***] | [***] | ||||
| TR1-2309 | TR1-2309: AXIALIF 45MM 10 X 11 IMPT | [***] | [***] | [***] | ||||
| TR1-2323 | TR1-2323: AXIALIF 40MM 10 X 10 IMPT | [***] | [***] | [***] | ||||
| TR1-2324 | TR1-2324: AXIALIF 45MM 10 X 10 IMPT | [***] | [***] | [***] | ||||
| TR1-2301 | TR1-2301: AXIALIF 40MM 10 X 12 IMP | [***] | [***] | [***] | ||||
| TR1-2310 | TR1-2310: AXIALIF 45MM 10 X 12 IMPT | [***] | [***] | [***] | ||||
| TR1-2325 | TR1-2325: AXIALIF 50MM 10 X 10 IMPT | [***] | [***] | [***] | ||||
| TR1-2326 | TR1-2326: AXIALIF 55MM 10 X 10 IMPT | [***] | [***] | [***] | ||||
| TR1-2303 | TR1-2303: AXIALIF 50MM 10 X 11 IMPT | [***] | [***] | [***] | ||||
| TR1-2320 | TR1-2320: AXIALIF 55MM 10 X 11 IMPT | [***] | [***] | [***] | ||||
| TR1-2304 | TR1-2304: AXIALIF 50MM 10 X 12 IMPT | [***] | [***] | [***] |
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 22 |
| EXECUTION COPY |
| TR1-2306 | TR1-2306: AXIALIF 60MM 10 X 11 IMPT | [***] | [***] | [***] | ||||
| TR1-2321 | TR1-2321: AXIALIF 55MM 10 X 12 IMPT | [***] | [***] | [***] | ||||
| TR1-2302 | TR1-2302: AXIALIF 40MM 9 X 12 IMPT | [***] | [***] | [***] | ||||
| TR1-2305 | TR1-2305: AXIALIF 50MM 9 X 12 IMPT | [***] | [***] | [***] | ||||
| TR1-2307 | TR1-2307: AXIALIF 60MM 10 X 12 IMPT | [***] | [***] | [***] | ||||
| TR1-2308 | TR1-2308: AXIALIF 60MM 9 X 12 IMPT | [***] | [***] | [***] | ||||
| TR1-2311 | TR1-2311: AXIALIF 45MM 9 X 12 IMPT | [***] | [***] | [***] | ||||
| TR1-2318 | TR1-2318: 2L 60MM 10 X 11 L4-L5 IMP | [***] | [***] | [***] | ||||
| TR1-2319 | TR1-2319: 2L 60MM 10 X 12 L4-L5 IMP | [***] | [***] | [***] | ||||
| TR1-2322 | TR1-2322: AXIALIF 55MM 9 X 12 IMPT | [***] | [***] | [***] | ||||
| TR1-2327 | TR1-2327: AXIALIF 60MM 10 X 10 IMPT | [***] | [***] | [***] | ||||
| TR1-2328 | TR1-2328: REV ROD, 40MM 10 X 10 | [***] | [***] | [***] | ||||
| TR1-2329 | TR1-2329: REV ROD, 40MM 10 X 11 | [***] | [***] | [***] | ||||
| TR1-2330 | TR1-2330: REV ROD, 40MM 10 X 12 | [***] | [***] | [***] | ||||
| TR1-2331 | TR1-2331: REV ROD, 40MM 9 X 12 | [***] | [***] | [***] | ||||
| TR1-2332 | TR1-2332: REV ROD, 45MM 10 X 10 | [***] | [***] | [***] | ||||
| TR1-2333 | TR1-2333: REV ROD, 45MM 10 X 11 | [***] | [***] | [***] | ||||
| TR1-2334 | TR1-2334: REV ROD, 45MM 10 X 12 | [***] | [***] | [***] | ||||
| TR1-2335 | TR1-2335: REV ROD, 45MM 9 X 12 | [***] | [***] | [***] | ||||
| TR1-2336 | TR1-2336: REV ROD, 50MM 10 X 10 | [***] | [***] | [***] | ||||
| TR1-2337 | TR1-2337: REV ROD, 50MM 10 X 11 | [***] | [***] | [***] | ||||
| TR1-2338 | TR1-2338: REV ROD, 50MM 10 X 12 | [***] | [***] | [***] | ||||
| TR1-2339 | TR1-2339: REV ROD, 50MM 9 X 12 | [***] | [***] | [***] | ||||
| TR1-2340 | TR1-2340: REV ROD, 55MM 10 X 10 | [***] | [***] | [***] | ||||
| TR1-2341 | TR1-2341: REV ROD, 55MM 10 X 11 | [***] | [***] | [***] | ||||
| TR1-2342 | TR1-2342: REV ROD, 55MM 10 X 12 | [***] | [***] | [***] | ||||
| TR1-2343 | TR1-2343: REV ROD, 55MM 9 X 12 | [***] | [***] | [***] | ||||
| TR1-2344 | TR1-2344: REV ROD, 60MM 10 X 10 | [***] | [***] | [***] | ||||
| TR1-2345 | TR1-2345: REV ROD, 60MM 10 X 11 | [***] | [***] | [***] | ||||
| TR1-2347 | TR1-2347: REV ROD, 60MM 10 X 12 | [***] | [***] | [***] | ||||
| TR1-2348 | TR1-2348: REV ROD, 60MM 9 X 12 | [***] | [***] | [***] | ||||
| Sub Total for AxiaLIF 1L Implants | [***] | [***] | ||||||
| 2L Implants* | ||||||||
| Catalog # | Description | Units | Each | Total | ||||
| TR1-2312 | TR1-2312: 2L 25MM S1 IMPLANT | [***] | [***] | [***] | ||||
| TR1-2313 | TR1-2313: 2L 30MM S1 IMPLANT | [***] | [***] | [***] | ||||
| TR1-2349 | TR1-2349 2L 35 MM S1 IMPLANT | [***] | [***] | [***] | ||||
| TR1-2314 | TR1-2314: 2L 50MM 10 X 11 L4-L5 IMP | [***] | [***] | [***] | ||||
| TR1-2315 | TR1-2315: 2L 50MM 10 X 12 L4-L5 IMP | [***] | [***] | [***] | ||||
| TR1-2316 | TR1-2316: 2L 55MM 10 X 11 L4-L5 IMP | [***] | [***] | [***] |
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 23 |
| EXECUTION COPY |
| TR1-2317 | TR1-2317: 2L 55MM 10 X 12 L4-L5 IMP | [***] | [***] | [***] | ||||
| TR1-2350 | TR1-2350: 2L 65MM 10 X 11 L4-L5 IMP | [***] | [***] | [***] | ||||
| TR1-2351 | TR1-2351: 2L 65MM 10 X 12 L4-L5 IMP | [***] | [***] | [***] | ||||
| Sub Total for AxiaLIF 2L Implants | [***] | [***] | ||||||
*Each 2L Implant Product consists of 1 Unit of S1 Implant and 1 Unit of L5 Implant. Accordingly, the [***] units listed here constitutes [***] of the S1 Implant units and [***]% of the L5 Implant units required to meet the obligation to purchase 100 2L Implant Products as part of the Initial Order.
| TR1-2200 | 1L Single use Kit (no charge for every 1L implant and for every L4-L5 2L anchor) | [***] | [***] | [***] | ||||
| TR1-2346 | TR1-2346: AXIALIF UNIVERSAL PLUG | [***] | [***] | [***] | ||||
| TR1-2207 | 2L Single Use Kit for Every 1L S1 anchor | [***] | [***] | [***] | ||||
| 1L resuable instrument set | [***] | [***] | [***] | |||||
| 2L reusable instrument set | [***] | [***] | [***] | |||||
| Sub Total for AxiaLIF Instruments Implants | [***] | [***] | ||||||
| Catalog # | Description | Units | Each | Total | ||||
| TR1-2700 | TR1-2700: TRANS-FACET INSTRUMENTS | [***] | [***] | [***] | ||||
| TR1-2701 | TR1-2701: FACET K-WIRE | [***] | [***] | [***] | ||||
| TR1-2824 | TR1-2824: 5MM X 25MM FAC SCRW SET | [***] | [***] | [***] | ||||
| TR1-2825 | TR1-2825: 5MM X 30MM FAC SCRW SET | [***] | [***] | [***] | ||||
| TR1-2826 | TR1-2826: 5MM X 35MM FAC SCRW SET | [***] | [***] | [***] | ||||
| TR1-2827 | TR1-2827: 5MM X 40MM FAC SCRW SET | [***] | [***] | [***] | ||||
| TR1-2828 | TR1-2828: 5MM X 25MM LAG SCREW SET | [***] | [***] | [***] | ||||
| TR1-2829 | TR1-2829: 5MM X 30MM LAG SCREW SET | [***] | [***] | [***] | ||||
| TR1-2830 | TR1-2830: 5MM X 35MM LAG SCREW SET | [***] | [***] | [***] | ||||
| TR1-2831 | TR1-2831: 5MM X 40MM LAG SCREW SET | [***] | [***] | [***] | ||||
| SubTotal For Facet Screws | [***] | |||||||
| Total for AxiaLIF and Facet Screws | [***] | |||||||
[***] Confidential treatment requested pursuant to a request for confidential treatment filed with the Securities and Exchange Commission. Omitted portions have been filed separately with the Commission.
| 24 |